COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill

House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.

Autumn Capital Hill Panorama
House looks to boost domestic pharma manufacturing

The coronavirus supplemental appropriations bill (H.R. 6379) introduced in the House on 23 March would increase both US pharmaceutical manufacturing capacity and scrutiny of foreign pharmaceutical supply chain risks, reflecting growing concerns among US legislators about foreign dependence, particularly on China.

This would all be done as a response to the COVID-19 viral outbreak that, because it began in China and...

More from Legislation

More from Pink Sheet